The YpsoMate autoinjector is designed for ease of use, allowing individuals with limited grip strength or vision to administer their medication safely and effortlessly. Credit: Ypsomed Group.

Global medical technology company BD has entered into a strategic partnership with Ypsomed, an injection systems manufacturer, to advance self-injection solutions specifically designed for high-viscosity biologic drugs.

The collaboration focuses on integrating BD’s Neopak XtraFlow glass prefillable syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform to address the current challenges of delivering biologic drugs that have a higher viscosity (thickness) of more than 15 centipoise.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The BD Neopak XtraFlow Glass Prefillable Syringe is the latest addition to BD’s portfolio, having an 8mm needle and a thinner wall cannula that improves the subcutaneous delivery of biologics with higher viscosity profiles.

This advancement aims to push the boundaries of flow and usability, surpassing the capabilities of standard half-inch needles.

Ypsomed will expand its YpsoMate 2.25 autoinjector platform to accommodate BD’s new syringe format.

Adjustments will be made for the shorter needle, alongside tooling and assembly qualification and comprehensive technical testing to ensure device reliability.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The YpsoMate autoinjector is designed for ease of use, allowing individuals with limited grip strength or vision to administer their medication safely and effortlessly.

Ypsomed Delivery Systems chief business officer Ulrike Bauer said: “We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak XtraFlow glass prefillable syringe with the YpsoMate 2.25 autoinjector.”

BD Pharmaceutical Systems worldwide president Patrick Jeukenne said: “Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem.

“These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”    

In August 2024, Astria Therapeutics selected Ypsomed’s Ypsomate autoinjector as its partner for the administration of STAR-0215 for the treatment of hereditary angioedema.